HUBBARD, Ohio, Jan. 10, 2012 /PRNewswire/ -- NanoLogix Inc.
(PINK SHEETS: NNLX), an innovator in the accelerated detection,
identification and antibiotic sensitivity determination of live
bacteria announces that has instructed a third-party to prepare a
total of six applications for submittal to the US FDA. The
applications are to include:
- Results of third-party TB tests for approval for use as a BSL-3
test process for Tuberculosis using NanoLogix BNP technology.
- Results of the University of Texas Health Science
Center-Houston Group B Streptococcus tests (currently ongoing) for
use as a recognized test kit using NanoLogix BNF technology.
- Results of multiple third-party tests on gram-positive bacteria
with BNP and BNF technologies for approval as recognized tests for
the gram-positive family of bacteria.
- Results of multiple third-party tests on gram-negative bacteria
with BNP and BNF technologies for approval as recognized tests for
the gram-negative family of bacteria.
"We are excited to have the process of preparation for FDA
submittal moving forward with a third-party," said NanoLogix CEO
Bret Barnhizer. "The accuracy of the
data and the expertise of the third-party in FDA submittals
provides us with confidence that the submittal process will run
smoothly and successfully. While it takes the timeline out of our
hands, it frees NanoLogix staff and resources to focus on further
research and development of our technologies."
Entry Into Food Testing
NanoLogix is currently working with a third-party to develop a
unique antibody for Listeria for use in pre-screening food
packaging, food processing equipment and preparation surfaces and
work areas. Tests of the efficacy of the antibody will occur at
client facilities.
Patents Granted and Newly Filed
NanoLogix is pleased to announce it has received two additional
patents for its BNC technology. The first is a foundational patent
by China. The second (Patent No.
US 8,067,154 B2) details how the NanoLogix BNC technology
changes the shape of micro-colonies, thus allowing for more rapid
detection and counting of cells. The company has multiple patent
applications pending in China,
India, Brazil, Japan, Russia
and Europe for their BNC, BNP and
BNF (BioNanoFilter) detection technologies.
In addition, the company this week filed a patent application
under the International Patent Cooperation Treaty for a significant
addition to its detection technology library.
American Journal of Perinatology Prints Group B Streptococcus
Research Using NanoLogix Biotechnology
The peer-reviewed Group B Strep research from the University of Texas Health Science Center –
Houston, previously available
online, appeared in the November print issue of the American
Journal of Perinatology. The research shows NanoLogix BNF test
results for viable Group B Strep (GBS) in a total of 4 to 6 Hours.
Established in 1983, the journal is the definitive forum for
specialists in obstetrics, neonatology, perinatology, and
maternal/fetal medicine, with emphasis on bridging the different
fields.
About NanoLogix, Inc.
NanoLogix is a biotechnology company focused primarily on rapid
diagnostics. Its products offer accelerated detection and
identification of microorganisms. In addition to medical and
homeland security applications, NanoLogix technology is applicable
in pharmaceutical, industrial, veterinary and environmental
testing.
Patents granted to NanoLogix can be used in the areas of applied
microbiology, soil microbiology and bioremediation, microbial
physiology, molecular biology, pharmacology, pharmaco-kinetics, and
antibiotic sensitivity
For more information visit www.nanologix.com.
Media Contact:
Lisa Ann Pinkerton
650-288-1824
Lisaann@technicacommunications.com
Investor Contact:
Carol Surrena
NanoLogix, Inc.
330-534-0800
carol@nanologix.com
This press release contains statements, which may constitute
"forward- looking statements" within the meaning of the Securities
Act of 1933 and the Securities Exchange Act of 1934, as amended by
the Private Securities Litigation Reform Act of 1995. Those
statements include statements regarding the intent, belief or
current expectations of NanoLogix, Inc., and members of its
management as well as the assumptions on which such statements are
based. Prospective investors are cautioned that any such
forward-looking statements are not guarantees of future performance
and involve risks and uncertainties, and that actual results may
differ materially from those contemplated by such forward-looking
statements. The Company undertakes no obligation to update or
revise forward-looking statements to reflect changed assumptions,
the occurrence of unanticipated events or changes to future
operating results.
SOURCE NanoLogix, Inc.